Hidradenitis Suppurativa

UCB announced that a new dosing option for bimekizumab-bkzx is now available through prescription for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

These findings highlight the value in understanding and recognizing gender differences in patient experiences with hidradenitis suppurativa and their impact on life quality.

Patients in this post-hoc analysis with elevated CRP were found to have a higher BMI and more severe hidradenitis suppurativa.

In this analysis, a retrospective and multi-center study was conducted to determine any predictors of biological therapy intensification in individuals with HS.

In this analysis, investigators conducted a systematic review of studies evaluating the effects of smoking tobacco on surgical outcomes for those with hidradenitis suppurativa.

Study findings suggest an interplay between social determinants of health and HS, especially among underrepresented patient populations.

In the fifth and final video from this series, experts discuss future research priorities and opportunities in hidradenitis suppurativa.

In part 4 of our series, expert dermatologists discuss the safety profile of bimekizumab in HS relative to other disease states and trials.

In this video series segment, expert dermatologsts prove ide insight into the strengths and limitations of IL-17 A/F inhibition in HS.

Expert dermatologists discuss the role of IL-17 A/F inhibition in the management of hidradenitis suppurativa.

In this 5-part, expert-led series, a pair of dermatologists break down how the FDA approval of bimekizumab impacts the treatment landscape of HS.

This meta-analysis showed that both secondary closure techniques substantially reduce the risk of hidradenitis suppurativa recurrence compared to primary direct closure.

UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS.

These data on patients with hidradenitis suppurativa point to several factors as being associated with diagnostic wandering.

This analysis highlighted links between depression, stigmatization, anxiety, and health- and disease-related variables among individuals with HS in Europe.

Findings suggest HS is associated with pregnancy complications and adverse outcomes for both mothers and offspring.

This analysis was conducted to evaluate whether genetic risk of hidradenitis suppurativa was linked to greater risk of future cardiometabolic disease.

Contrary to previous research, findings suggest no significant difference in infertility between patients with HS, other dermatological diseases, and healthy controls.

These new data demonstrate that bimekizumab was both effective and well-tolerated over the course of 2 years for patients with hidradenitis suppurativa.

Adding semaglutide to standard hidradenitis suppurative therapies achieved improvements in quality of life and fewer disease-related flares.

A new case-control study reported a higher prevalence of precocious puberty in children and adolescents with HS compared with controls.

These findings resulted from a systematic literature review highlighting the impact of stigma and lack of support on self-image for patients with eczema, psoriasis, HS, and other conditions.

A study involving 6.2 million patients found smoking increases the risk of developing hidradenitis suppurativa, with quitting smoking significantly reducing this risk.

A phase 2 trial shows tofacitinib improves autoimmune conditions in Down syndrome, with notable skin health benefits and a good safety profile.

These data show that izokibep treatment of HS met each of its key primary and key secondary endpoints.